𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A double blind placebo-controlled trial using intravenous zoledronate (CGP-42446) in patients with paget’s disease of bone

✍ Scribed by V. Schaffer; H. Buckler; W. Ryan; P. Richardson


Publisher
Springer-Verlag
Year
1996
Tongue
English
Weight
144 KB
Volume
6
Category
Article
ISSN
0937-941X

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


A double-blind, placebo-controlled singl
✍ Lisa Templeton; Andrew Barker; Keith Wesnes; David Wilkinson 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB 👁 2 views

Benzodiazepine agonists have been shown to reduce cognitive functioning by producing attentional de®cits similar to those produced by muscarinic antagonists. It has therefore been postulated that benzodiazepine antagonists may improve cognitive function in patients with Alzheimer's disease by indire

A randomized, double-blind, placebo-cont
✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to

Gabapentin in patients with the pruritus
✍ Nora V. Bergasa; Monnie McGee; Iona H. Ginsburg; Danielle Engler 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 420 KB 👁 2 views

Pruritus is defined as the second order of nociception, the first being pain; thus, there is a rationale to study gabapentin, a drug that increases the threshold to experience nociception. The aim of this double-blind, randomized, placebo-controlled trial was to study the effect of gabapentin on the

A 24-week, double-blind, placebo-control
✍ Vee. P. Prasher; Adam Huxley; M. S. Haque 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

## Abstract ## Background Donepezil Hydrochloride (Aricept) is a selective anticholinesterase inhibitor developed for the treatment of Alzheimer's disease (AD). This study investigated the safety and efficacy of the drug to treat Down syndrome (DS) adults with mild to moderate AD. ## Method This